The role of nuclear medicine in the diagnosis of cancer of unknown origin

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

The role of nuclear medicine in the diagnosis of cancer of unknown origin. / Demir, H; Berk, F; Raderer, M; Plowman, P N; Lassen, U; Daugaard, G; Clausen, M; Bohuslavizki, K H; Peters, M; Harmer, C; Malamitsi, J; Aktolun, C.

In: American Journal of Nuclear Medicine and Molecular Imaging, Vol. 48, No. 2, 06.2004, p. 164-73.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Demir, H, Berk, F, Raderer, M, Plowman, PN, Lassen, U, Daugaard, G, Clausen, M, Bohuslavizki, KH, Peters, M, Harmer, C, Malamitsi, J & Aktolun, C 2004, 'The role of nuclear medicine in the diagnosis of cancer of unknown origin', American Journal of Nuclear Medicine and Molecular Imaging, vol. 48, no. 2, pp. 164-73.

APA

Demir, H., Berk, F., Raderer, M., Plowman, P. N., Lassen, U., Daugaard, G., ... Aktolun, C. (2004). The role of nuclear medicine in the diagnosis of cancer of unknown origin. American Journal of Nuclear Medicine and Molecular Imaging, 48(2), 164-73.

Vancouver

Demir H, Berk F, Raderer M, Plowman PN, Lassen U, Daugaard G et al. The role of nuclear medicine in the diagnosis of cancer of unknown origin. American Journal of Nuclear Medicine and Molecular Imaging. 2004 Jun;48(2):164-73.

Author

Demir, H ; Berk, F ; Raderer, M ; Plowman, P N ; Lassen, U ; Daugaard, G ; Clausen, M ; Bohuslavizki, K H ; Peters, M ; Harmer, C ; Malamitsi, J ; Aktolun, C. / The role of nuclear medicine in the diagnosis of cancer of unknown origin. In: American Journal of Nuclear Medicine and Molecular Imaging. 2004 ; Vol. 48, No. 2. pp. 164-73.

Bibtex

@article{146b5a6d67734db2ad5ce47ed8d16035,
title = "The role of nuclear medicine in the diagnosis of cancer of unknown origin",
abstract = "Cancer of unknown origin (CUO) is defined by the absence of any primary tumour in biopsy-proved metastatic cancer. CUO accounts for a 5-10{\%} of all malignancies. These tumors have a specific biology with clinical characteristics of rapid progression and atypical metastases. Diagnostic evaluation is directed at the identification of treatable subset. Accurate diagnostic workup is crucial because both prognosis and survival rates depend mainly on detection of the primary tumor site. Although these patients undergo extensive imaging procedures, nuclear medicine techniques are under-utilized despite their ability of providing molecular information. Positron emission tomography has an emerging role in this clinical challenge along with other nuclear medicine methods including, bone scan, thyroid scintigraphy.",
keywords = "Biomarkers, Tumor, Bone Neoplasms, Bone and Bones, Fluorodeoxyglucose F18, Humans, Lymphatic Metastasis, Neoplasms, Unknown Primary, Prognosis, Radiopharmaceuticals, Tomography, Emission-Computed, Tomography, Emission-Computed, Single-Photon, Journal Article, Review",
author = "H Demir and F Berk and M Raderer and Plowman, {P N} and U Lassen and G Daugaard and M Clausen and Bohuslavizki, {K H} and M Peters and C Harmer and J Malamitsi and C Aktolun",
year = "2004",
month = "6",
language = "English",
volume = "48",
pages = "164--73",
journal = "American Journal of Nuclear Medicine and Molecular Imaging",
issn = "2160-8407",
publisher = "e-Century Publishing Corporation",
number = "2",

}

RIS

TY - JOUR

T1 - The role of nuclear medicine in the diagnosis of cancer of unknown origin

AU - Demir, H

AU - Berk, F

AU - Raderer, M

AU - Plowman, P N

AU - Lassen, U

AU - Daugaard, G

AU - Clausen, M

AU - Bohuslavizki, K H

AU - Peters, M

AU - Harmer, C

AU - Malamitsi, J

AU - Aktolun, C

PY - 2004/6

Y1 - 2004/6

N2 - Cancer of unknown origin (CUO) is defined by the absence of any primary tumour in biopsy-proved metastatic cancer. CUO accounts for a 5-10% of all malignancies. These tumors have a specific biology with clinical characteristics of rapid progression and atypical metastases. Diagnostic evaluation is directed at the identification of treatable subset. Accurate diagnostic workup is crucial because both prognosis and survival rates depend mainly on detection of the primary tumor site. Although these patients undergo extensive imaging procedures, nuclear medicine techniques are under-utilized despite their ability of providing molecular information. Positron emission tomography has an emerging role in this clinical challenge along with other nuclear medicine methods including, bone scan, thyroid scintigraphy.

AB - Cancer of unknown origin (CUO) is defined by the absence of any primary tumour in biopsy-proved metastatic cancer. CUO accounts for a 5-10% of all malignancies. These tumors have a specific biology with clinical characteristics of rapid progression and atypical metastases. Diagnostic evaluation is directed at the identification of treatable subset. Accurate diagnostic workup is crucial because both prognosis and survival rates depend mainly on detection of the primary tumor site. Although these patients undergo extensive imaging procedures, nuclear medicine techniques are under-utilized despite their ability of providing molecular information. Positron emission tomography has an emerging role in this clinical challenge along with other nuclear medicine methods including, bone scan, thyroid scintigraphy.

KW - Biomarkers, Tumor

KW - Bone Neoplasms

KW - Bone and Bones

KW - Fluorodeoxyglucose F18

KW - Humans

KW - Lymphatic Metastasis

KW - Neoplasms, Unknown Primary

KW - Prognosis

KW - Radiopharmaceuticals

KW - Tomography, Emission-Computed

KW - Tomography, Emission-Computed, Single-Photon

KW - Journal Article

KW - Review

M3 - Journal article

C2 - 15243411

VL - 48

SP - 164

EP - 173

JO - American Journal of Nuclear Medicine and Molecular Imaging

JF - American Journal of Nuclear Medicine and Molecular Imaging

SN - 2160-8407

IS - 2

ER -

ID: 167431879